Alexandre Huber1, Stéphanie J Seidler2, Daniela E Huber2. 1. Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. 2. Gynecology Department, Hôpital du Valais, Sierre, Switzerland.
Abstract
OBJECTIVE: To evaluate the prognosis, the patient and tumor characteristics, and the treatment of bilateral breast cancer (BBC) and to compare synchronous (sBBC) and metachronous BBC (mBBC). MATERIALS AND METHODS: For this retrospective study, data from 123 consecutive BBC patients (56 sBBC and 67 mBBC) that were presented at the Sion Hospital tumor board between 2007 and 2018 were collected retrospectively. RESULTS: Mean follow-up was 85 months. 2nd tumors in both groups were more often diagnosed radiologically. Mean time interval between mBBC was 115 months. A shorter interval was positively correlated with a negative hormonal receptor (HR) status and higher grade for the 2nd tumor. There was no difference in overall survival (OS) and relapse-free survival (RFS) between sBBC and mBBC. OS was longer if both tumors were hormonal receptor (HR) positive. mBBC exhibited a higher local recurrence rate than sBBC (p=0.03). CONCLUSION: sBBC and mBBC patients did not show any difference in OS or RFS, although mBBC patients were more prone to local relapses.
OBJECTIVE: To evaluate the prognosis, the patient and tumor characteristics, and the treatment of bilateral breast cancer (BBC) and to compare synchronous (sBBC) and metachronous BBC (mBBC). MATERIALS AND METHODS: For this retrospective study, data from 123 consecutive BBC patients (56 sBBC and 67 mBBC) that were presented at the Sion Hospital tumor board between 2007 and 2018 were collected retrospectively. RESULTS: Mean follow-up was 85 months. 2nd tumors in both groups were more often diagnosed radiologically. Mean time interval between mBBC was 115 months. A shorter interval was positively correlated with a negative hormonal receptor (HR) status and higher grade for the 2nd tumor. There was no difference in overall survival (OS) and relapse-free survival (RFS) between sBBC and mBBC. OS was longer if both tumors were hormonal receptor (HR) positive. mBBC exhibited a higher local recurrence rate than sBBC (p=0.03). CONCLUSION: sBBC and mBBC patients did not show any difference in OS or RFS, although mBBC patients were more prone to local relapses.
Authors: Hector D Vuoto; Alejandra M García; Gabriela B Candás; Agustina Gonzalez Zimmermann; Juan Luis Uriburu; Juan A M Isetta; Lucas Cogorno; Marina Khoury; Oscar L Bernabó Journal: Breast J Date: 2010 Nov-Dec Impact factor: 2.431
Authors: Brigitte Rack; Christian Schindlbeck; Julia Jückstock; Ulrich Andergassen; Philip Hepp; Thomas Zwingers; Thomas W P Friedl; Ralf Lorenz; Hans Tesch; Peter A Fasching; Tanja Fehm; Andreas Schneeweiss; Werner Lichtenegger; Matthias W Beckmann; Klaus Friese; Klaus Pantel; Wolfgang Janni Journal: J Natl Cancer Inst Date: 2014-05-15 Impact factor: 13.506